Corporate GovernanceMay 4, 2026, 07:07 AM
Apellis Amends Executive Separation Plan Ahead of Biogen Merger
AI Summary
Apellis Pharmaceuticals' compensation committee approved an amendment and restatement of its Executive Separation Benefits and Retention Plan on April 28, 2026. These changes are in connection with the company's pending merger with Biogen Inc. The amended plan, effective upon the merger's closing, accelerates the vesting of unvested Converted Options and RSU Awards for participants upon qualifying termination or resignation. Additionally, C-Level Officers can claim "Good Reason" for resignation if their scope changes due to the company becoming a subsidiary, which was previously excluded.
Key Highlights
- Apellis Pharmaceuticals amended its Executive Separation Benefits and Retention Plan on April 28, 2026.
- The amendments are in connection with the pending merger with Biogen Inc.
- Unvested Converted Options and RSU Awards will fully vest upon qualifying termination or resignation.
- This acceleration applies to all plan participants, including named executive officers.
- C-Level Officers can claim "Good Reason" for resignation if their scope changes post-merger.
- The amended plan becomes effective upon the merger's Closing Date.